Application and risk prediction of thrombolytic therapy in cardio-cerebrovascular diseases: a review

Thrombosis Journal

Research

Kexin Zhang¹  Hongling Zhu¹  Hesong Zeng¹  Yao Jiang¹ 

[1] Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430030, Wuhan, Hubei, China;

关键词: Ischemic stroke;    Myocardial infarction;    Machine learning;    Risk assessment;    Thrombolytic therapy;   

DOI  :  10.1186/s12959-023-00532-0

 received in 2023-03-21, accepted in 2023-08-18,  发布年份 2023

来源: Springer

【 摘 要 】

Cardiocerebrovascular diseases (CVDs) are the leading cause of death worldwide, consuming huge healthcare budget. For CVD patients, the prompt assessment and appropriate administration is the crux to save life and improve prognosis. Thrombolytic therapy, as a non-invasive approach to achieve recanalization, is the basic component of CVD treatment. Still, there are risks that limits its application. The objective of this review is to give an introduction on the utilization of thrombolytic therapy in cardiocerebrovascular blockage diseases, including coronary heart disease and ischemic stroke, and to review the development in risk assessment of thrombolytic therapy, comparing the performance of traditional scales and novel artificial intelligence-based risk assessment models.

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023

【 图 表 】

13690_2023_1170_Article_IEq200.gif

12888_2023_5142_Article_IEq20.gif

Fig. 3